niacinamide has been researched along with Liver Failure in 4 studies
nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.
Liver Failure: Severe inability of the LIVER to perform its normal metabolic functions, as evidenced by severe JAUNDICE and abnormal serum levels of AMMONIA; BILIRUBIN; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; LACTATE DEHYDROGENASES; and albumin/globulin ratio. (Blakiston's Gould Medical Dictionary, 4th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| "For the first time ever, sorafenib-induced hepatic failure has been cured by liver transplantation." | 7.79 | Liver transplantation treating the patient with hepatic failure associated with sorafenib treatment: report of a case. ( Feng, M; Li, G; Lu, L; Qian, X; Rao, J; Wang, X; Zhang, F, 2013) |
| "Sorafenib has been shown to improve survival of patients with advanced hepatocellular carcinoma (HCC)." | 7.78 | Clinical course of sorafenib treatment in patients with hepatocellular carcinoma. ( Cho, M; Heo, J; Kang, DH; Kim, GH; Song, GA; Woo, HY; Yoon, KT, 2012) |
| "For the first time ever, sorafenib-induced hepatic failure has been cured by liver transplantation." | 3.79 | Liver transplantation treating the patient with hepatic failure associated with sorafenib treatment: report of a case. ( Feng, M; Li, G; Lu, L; Qian, X; Rao, J; Wang, X; Zhang, F, 2013) |
| "Sorafenib has been shown to improve survival of patients with advanced hepatocellular carcinoma (HCC)." | 3.78 | Clinical course of sorafenib treatment in patients with hepatocellular carcinoma. ( Cho, M; Heo, J; Kang, DH; Kim, GH; Song, GA; Woo, HY; Yoon, KT, 2012) |
| " This report describes the findings from 2 phase 1 studies assessing the pharmacokinetic (PK) profile of a single dose of asciminib (40 mg) in individuals with impaired renal function (based on absolute glomerular filtration rate; NCT03605277) or impaired hepatic function (based on Child-Pugh classification; NCT02857868)." | 3.01 | Pharmacokinetics of Asciminib in Individuals With Hepatic or Renal Impairment. ( Aimone, P; Allepuz, A; Hoch, M; Hourcade-Potelleret, F; Quinlan, M; Sato, M; Sengupta, T; Zack, J, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hoch, M | 1 |
| Sato, M | 1 |
| Zack, J | 1 |
| Quinlan, M | 1 |
| Sengupta, T | 1 |
| Allepuz, A | 1 |
| Aimone, P | 1 |
| Hourcade-Potelleret, F | 1 |
| Rao, J | 1 |
| Feng, M | 1 |
| Qian, X | 1 |
| Li, G | 1 |
| Wang, X | 1 |
| Zhang, F | 1 |
| Lu, L | 1 |
| Schramm, C | 1 |
| Schuch, G | 1 |
| Lohse, AW | 1 |
| Woo, HY | 1 |
| Heo, J | 1 |
| Yoon, KT | 1 |
| Kim, GH | 1 |
| Kang, DH | 1 |
| Song, GA | 1 |
| Cho, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase I, Open-label and Single-dose Study to Evaluate the Pharmacokinetics and Safety of a Single 40 mg Oral Dose of ABL001 (Asciminib) in Subjects With Impaired Renal Function Compared to Matched Control Subjects With Normal Renal Function[NCT03605277] | Phase 1 | 14 participants (Actual) | Interventional | 2018-11-16 | Completed | ||
| A Phase I, Open-label, Multi-center, Single-dose Study to Evaluate the Pharmacokinetics of ABL001 in Healthy Subjects With Normal Hepatic Function and Subjects With Impaired Hepatic Function[NCT02857868] | Phase 1 | 32 participants (Actual) | Interventional | 2016-05-03 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for niacinamide and Liver Failure
| Article | Year |
|---|---|
Pharmacokinetics of Asciminib in Individuals With Hepatic or Renal Impairment.
Topics: Aged; Area Under Curve; Female; Glomerular Filtration Rate; Half-Life; Humans; Liver Failure; Male; | 2021 |
Pharmacokinetics of Asciminib in Individuals With Hepatic or Renal Impairment.
Topics: Aged; Area Under Curve; Female; Glomerular Filtration Rate; Half-Life; Humans; Liver Failure; Male; | 2021 |
Pharmacokinetics of Asciminib in Individuals With Hepatic or Renal Impairment.
Topics: Aged; Area Under Curve; Female; Glomerular Filtration Rate; Half-Life; Humans; Liver Failure; Male; | 2021 |
Pharmacokinetics of Asciminib in Individuals With Hepatic or Renal Impairment.
Topics: Aged; Area Under Curve; Female; Glomerular Filtration Rate; Half-Life; Humans; Liver Failure; Male; | 2021 |
3 other studies available for niacinamide and Liver Failure
| Article | Year |
|---|---|
Liver transplantation treating the patient with hepatic failure associated with sorafenib treatment: report of a case.
Topics: Antineoplastic Agents; Humans; Liver Failure; Liver Transplantation; Male; Middle Aged; Niacinamide; | 2013 |
Sorafenib-induced liver failure.
Topics: Adenocarcinoma, Follicular; Aged; Antineoplastic Agents; Benzenesulfonates; Female; Humans; Liver Fa | 2008 |
Clinical course of sorafenib treatment in patients with hepatocellular carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Diarrhea; Disease | 2012 |